Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback